A New Government Act Could Disrupt the Biotech Industry

On this week's Stansberry Investor Hour, Dan and Corey welcome their colleague John Engel to the podcast. John is the lead equity analyst on the Stansberry Innovations Report newsletter, where he finds companies that are revolutionizing their respective industries with cutting-edge technology. He also works on Prosperity Investor, a newsletter that focuses on opportunities in the health care sector.

John kicks off the show by detailing the new Biosecure Act that's currently moving through Congress. Its purpose is to limit China's access to U.S. biological information. As he explains, this legislation is going to disrupt the industry, hurt biotech companies, and possibly even bankrupt the smaller players. But, conversely, it's going to allow other contract development and management organizations to replace Chinese ones, creating massive opportunities for investors. John also shares how he got his start in the biotech field at a fermentation lab and as a molecular biologist before shifting to the world of finance.

Next, John talks about the pandemic, vaccines, and the current bear market in biotech. He mentions one big story in biotech that he believes isn't getting enough attention – bispecific antibodies. This development allows one drug to hit two targets, so patients no longer have to receive two different drugs for treatment. This leads to a conversation about gene editing, personalized medicine, and rare diseases.

Finally, John delves into AI, Nvidia, and the "hype cycle" surrounding the technology. He points out that companies are desperate to use AI to their advantage, but for many of them, there's no use for it in their business. Plus, John discusses "advanced general intelligence," which involves systems that can reason like human beings.

0:00 Biosecure Act, China, John's background
20:13 Bispecific antibodies, gene editing, rare diseases
40:24 All things AI

[nunyabusiness]

Great interview with John Engel. But I must take exception to the off hand comment about where the gene editing may be occurring. While, I have no doubt that much of this work may be occurring overseas, I have to say that I find it hard to believe that American scientists with all of the latest technologies that they have access to aren't doing some 'exploring' of their own.

[jerrycrosby]

2 🎯 1 drug " What does that mean" great job Dan. Love the turn the gene 📴... fixed gene.007. WOW is right 👍. I don't know how AI is going to help Nestle or Hershey... but I'm probably wrong. 🙏 Gentlemen

[truemonk]

11 mins into the video….stupid commentary
23 mins…….still just garbage discussion

[andrewscott]

I'm clicking off now!! This piled high and deeper doesn't know his stuff. He knows only what he is allowed to in his cylo.
Question for the interested: Who is Dr Otto Warburg and for what did he win a Nobel prize?